HIGGINS JOHN L — SEC insider filings
SEC reporting owner CIK 1208906. 59 insider filings on record with FilingPulse; latest filed 2026-11-02.
Transaction summary — filings shown
Covers the 50 most recent of 59 filings on record, filed 2021-07-02 to 2026-11-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 4 filings — 272,011 shares, $505,939 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 17 legs across 11 filings — 97,104 shares, $4,522,297 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 101.
- Largest priced transaction: sale of 10,000 shares @ $78.32 ($783,173) in LIGAND PHARMACEUTICALS INC, filed 2022-11-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC (LGND) | Director | 18 | — | 6 legs · 29,000 sh · $2,419,440 | 23 |
| BIO-TECHNE Corp (TECH) | Director | 15 | — | 8 legs · 8,104 sh · $1,867,857 | 34 |
| OmniAb, Inc. (OABI) | Director | 17 | 5 legs · 272,011 sh · $505,939 | 3 legs · 60,000 sh · $235,000 | 44 |
Insider filings — HIGGINS JOHN L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-02 | 4 | BIO-TECHNE Corp (TECH) | Grant/award (A): 2,750 @ $0 | EDGAR |
| 2026-09-30 | 4 | BIO-TECHNE Corp (TECH) | Option exercise (M): 15,940 @ $0 · Tax withholding (F): 5,562 @ $72.51 · Option exercise (M): 15,940 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | OmniAb, Inc. (OABI) | Option exercise (M): 20,000 · Option exercise (M): 20,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | OmniAb, Inc. (OABI) | Option exercise (M): 13,172 · Option exercise (M): 13,172 (derivative) @ $0 | EDGAR |
| 2025-11-10 | 4 | OmniAb, Inc. (OABI) | Purchase (P): 36,223 @ $1.41 · Purchase (P): 41,038 @ $1.38 | EDGAR |
| 2025-11-03 | 4 | BIO-TECHNE Corp (TECH) | Grant/award (A): 1,640 @ $0 · Grant/award (A): 3,777 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | BIO-TECHNE Corp (TECH) | Option exercise (M): 5,040 @ $21.84 · Option exercise (M): 5,040 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | OmniAb, Inc. (OABI) | Option exercise (M): 20,000 · Option exercise (M): 20,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | OmniAb, Inc. (OABI) | Purchase (P): 65,000 @ $1.44 | EDGAR |
| 2025-05-05 | 4 | BIO-TECHNE Corp (TECH) | Option exercise (M): 12,000 @ $21.84 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | OmniAb, Inc. (OABI) | Purchase (P): 4,000 @ $2.28 | EDGAR |
| 2025-03-20 | 4 | OmniAb, Inc. (OABI) | Purchase (P): 125,750 @ $2.35 | EDGAR |
| 2025-01-30 | 4 | OmniAb, Inc. (OABI) | Option exercise (M): 13,172 · Option exercise (M): 13,172 (derivative) @ $0 | EDGAR |
| 2024-10-28 | 4 | BIO-TECHNE Corp (TECH) | Grant/award (A): 1,462 @ $0 · Grant/award (A): 3,511 (derivative) @ $0 | EDGAR |
| 2024-09-16 | 4 | BIO-TECHNE Corp (TECH) | Option exercise (M): 6,000 @ $22.95 · Tax withholding (F): 1,874 @ $73.20 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2024-07-10 | 4 | BIO-TECHNE Corp (TECH) | Option exercise (M): 6,000 @ $22.95 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | OmniAb, Inc. (OABI) | Option exercise (M): 20,000 · Option exercise (M): 20,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | BIO-TECHNE Corp (TECH) | Option exercise (M): 4,000 @ $22.95 · Sale (S): 4,000 @ $83.84 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2024-04-23 | 4/A | OmniAb, Inc. (OABI) | Grant/award (A): 2,427,861 | EDGAR |
| 2024-01-31 | 4 | OmniAb, Inc. (OABI) | Option exercise (M): 13,173 · Option exercise (M): 13,173 (derivative) @ $0 | EDGAR |
| 2023-10-30 | 4 | BIO-TECHNE Corp (TECH) | Grant/award (A): 1,625 @ $0 · Grant/award (A): 3,937 (derivative) @ $0 | EDGAR |
| 2023-06-27 | 4 | OmniAb, Inc. (OABI) | Tax withholding (F): 25,914 @ $3.66 · Tax withholding (F): 57,803 @ $3.23 · Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | OmniAb, Inc. (OABI) | Option exercise (M): 9,000 @ $3.68 · Sale (S): 9,000 @ $4.05 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
| 2023-05-23 | 4 | OmniAb, Inc. (OABI) | Option exercise (M): 1,000 @ $3.68 · Sale (S): 1,000 @ $4.05 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | OmniAb, Inc. (OABI) | Option exercise (M): 50,000 @ $3.68 · Sale (S): 50,000 @ $3.89 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2023-05-02 | 4 | BIO-TECHNE Corp (TECH) | Option exercise (M): 16,000 @ $21.85 · Tax withholding (F): 4,377 @ $79.88 · Option exercise (M): 16,000 (derivative) @ $0 | EDGAR |
| 2023-02-01 | 4 | OmniAb, Inc. (OABI) | Grant/award (A): 39,517 @ $0 · Grant/award (A): 142,020 (derivative) @ $0 | EDGAR |
| 2022-12-30 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Tax withholding (F): 5,289 @ $66.29 | EDGAR |
| 2022-12-27 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 92,932 (derivative) @ $0 | EDGAR |
| 2022-12-20 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 10,000 @ $61.87 | EDGAR |
| 2022-12-14 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 20,000 @ $12.78 · Disposition to issuer (D): 3,944 @ $64.80 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2022-12-01 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Tax withholding (F): 9,803 @ $72.90 | EDGAR |
| 2022-11-21 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 10,000 @ $78.32 · Option exercise (M): 10,000 @ $12.78 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2022-11-07 | 4/A | LIGAND PHARMACEUTICALS INC (LGND) | Holdings only — no transactions reported | EDGAR |
| 2022-11-03 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 45,922 @ $0 | EDGAR |
| 2022-11-03 | 4 | OmniAb, Inc. (OABI) | Grant/award (A): 2,176,521 · Option exercise (M): 246,648 @ $2.52 · Grant/award (A): 246,648 (derivative) · Grant/award (A): 61,362 (derivative) · Grant/award (A): 400,808 (derivative) · Grant/award (A): 232,971 (derivative) · +7 more | EDGAR |
| 2022-10-31 | 4 | BIO-TECHNE Corp (TECH) | Grant/award (A): 338 @ $0 · Grant/award (A): 865 (derivative) @ $0 | EDGAR |
| 2022-09-22 | 4/A | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 1,000 @ $88.06 | EDGAR |
| 2022-09-16 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 2,000 @ $90 · Sale (S): 3,000 @ $89.35 | EDGAR |
| 2022-08-12 | 4 | BIO-TECHNE Corp (TECH) | Option exercise (M): 3,400 @ $66.90 · Sale (S): 900 @ $373.99 · Sale (S): 100 @ $374.89 · Sale (S): 992 @ $380.15 · Sale (S): 504 @ $385.47 · Sale (S): 8 @ $380.71 · +1 more | EDGAR |
| 2022-07-06 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Other (J): 164 @ $75.84 | EDGAR |
| 2022-06-14 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 20,423 @ $0 | EDGAR |
| 2022-06-09 | 4 | BIO-TECHNE Corp (TECH) | Option exercise (M): 1,000 @ $66.90 · Sale (S): 1,000 @ $364.31 · Option exercise (M): 600 @ $66.90 · Sale (S): 600 @ $366.09 · Option exercise (M): 1,000 (derivative) @ $0 · Option exercise (M): 600 (derivative) @ $0 | EDGAR |
| 2022-05-10 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 8,000 @ $21.92 · Sale (S) @ $429,159.38 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2022-05-09 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 76,478 (derivative) @ $0 | EDGAR |
| 2022-02-16 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Tax withholding (F): 1,946 @ $123.68 · Tax withholding (F): 2,061 @ $123.68 · Tax withholding (F): 1,916 @ $123.68 | EDGAR |
| 2022-01-28 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 9,606 @ $0 · Grant/award (A): 13,560 @ $0 · Tax withholding (F): 3,060 @ $113.68 · Tax withholding (F): 6,183 @ $113.68 | EDGAR |
| 2021-11-12 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 3,000 @ $160.50 | EDGAR |
| 2021-11-01 | 4 | BIO-TECHNE Corp (TECH) | Grant/award (A): 194 @ $0 · Grant/award (A): 633 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Other (J): 247 @ $85.91 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1208906 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs